Inaxaplin

DB21521InvestigationalSmall molecule

Inaxaplin is a small molecule drug. Inaxaplin is under investigation in clinical trial NCT06794996 (Phase 2b Open-label Study of Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease). Inaxaplin has... Inaxaplin has a monoisotopic molecular weight of 417.13 Da.

Mechanism: Pharmacologically active on Apolipoprotein L1
Curator reviewed
Formula / weight: C₂₁H₁₈F₃N₃O₃ · 417.388 g/mol (avg)
Code names: VX-147

Resolves to

Compound

UNIIS2SJ2RVZ6YCAS2446816-88-0ChEMBLCHEMBL5083170ChEBI758601PubChem147289591

Structure

InChIKeyCTXLPYZCBOVVQK-UZLBHIALSA-NSMILESO[C@@H]1CNC(=O)[C@H]1NC(=O)CCC1=C(NC2=C(F)C=C(F)C=C12)C1=CC=C(F)C=C1

Targets

O14791APOL1

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Inaxaplin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account